Kuriyama M, Ichimori Y, Iwasa S, Tsukamoto K
Central Research Division, Takeda Chemical Industries, Ltd., Osaka, Japan.
Cytotechnology. 1990 Jan;3(1):31-7. doi: 10.1007/BF00365263.
A hybridoma secreting human monoclonal antibody (MAB) against Pseudomonas aeruginosa exotoxin A (PEA) was constructed by fusing Epstein-Barr virus-transformed peripheral blood lymphocytes with human B lymphoblastoid cell line TAW-925. The human-human hybridoma stably produced human IgG2 MAB at the rate of 0.4-0.5 microgram/ml per 10(6) cells per day for more than six months, and the MAB was capable of neutralizing the in vitro cytotoxic and in vivo lethal effects of PEA with approximately 100- and 70-fold, respectively, higher activity than serum polyclonal antibody preparations.
通过将爱泼斯坦-巴尔病毒转化的外周血淋巴细胞与人B淋巴母细胞系TAW-925融合,构建了一种分泌抗铜绿假单胞菌外毒素A(PEA)的人单克隆抗体(MAB)的杂交瘤。这人-人杂交瘤稳定地产生人IgG2 MAB,每天每10⁶个细胞的产量为0.4 - 0.5微克/毫升,持续了六个多月,并且该MAB能够中和PEA的体外细胞毒性和体内致死作用,其活性分别比血清多克隆抗体制剂高约100倍和70倍。